問卷

TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

徐偉勛
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

326Cases

2020-12-01 - 2024-05-24

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2021-04-01 - 2032-04-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2021-05-31 - 2026-09-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2021-06-01 - 2024-02-27

Phase I/II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

2026-07-01 - 2028-11-30

Phase II

Not yet recruiting
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Advanced Gastrointestinal (GI) Cancers
  • Condition/Disease

    Gastrointestinal Cancers

  • Test Drug

    Rina‑S

Participate Sites
5Sites

Not yet recruiting1Sites

2018-12-01 - 2019-11-07

Phase I

Active
A Phase I Multicenter Study of Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors (CLOVER)
  • Condition/Disease

    Carcinoma, Squamous Cell of Head and Neck Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma

  • Test Drug

    Durvalumab (MEDI4736) Tremelimumab

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting3Sites

2022-02-01 - 2022-04-06

Phase II

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2022-02-01 - 2028-09-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2022-02-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-03-01 - 2024-07-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites